Learning Objectives:
1. Understand the reasons for failure of TME-directed immunotherapeutics.
2. Review guiding principles for cancer immunotherapeutics development.
3. Understand potential approaches for increasing tumor-reactive T cells in patients, and reversing T Cell ignorance
Session date:
01/10/2022 - 12:00pm to 1:00pm CST
Location:
KCBD RM:1103
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Scott Antonia, MD, PhD